DelveInsight's "ROZLYTREK Market Size, Forecast, and Market Insight Report" highlights the details around ROZLYTREK, an ...
As biomarker testing and the demand for tumor-agnostic therapies rise, ROZLYTREK can potentially target a specialized yet valuable market segment. While competition from other TRK inhibitors ...
Bradley Bernstein, MD, PhD, A. Thomas Look, MD, and William R. Sellers, MD, of Dana-Farber Cancer Institute have been elected ...
The American Association for Cancer Research (AACR) today announced its newly elected 2025 class of Fellows of the AACR Academy.
The mesenchymal-epithelial transition (MET) gene is involved in signaling pathways that control ... The ROS1 mutation is similar to the ALK mutation. Some of the same drugs help treat both mutations.
TEVIMBRA is a monoclonal antibody that belongs to a class of drugs that bind to either the programmed death receptor-1 (PD-1) or PD-ligand 1 (PD-L1), blocking the PD-1/PD-L1 pathway ... increased ...
Hosted on MSN28d
Weakness in lung cancer's defenses found—an enzyme that boosts cancer cell metabolismWorking with mouse models and human cancer cells, the researchers identified a metabolic enzyme called GUK1 in lung cancers harboring an alteration in the ALK gene. Their experiments showed that ...
During embryonic development, the intestine of the Drosophila fly divides into distinct chambers thanks to the formation of ...
Targeted inhibition of a "signal jammer" protein may improve how tumors respond to immunotherapy. Published today in Nature, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback